Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?

Teng, Gim Gee; Tan-Koi, Wei-Chuen; Dong, Di; Sung, Cynthia

Teng, Gim Gee; Tan-Koi, Wei-Chuen; Dong, Di; Sung, Cynthia.

Affiliation

Teng GG; Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, 119228.
Tan-Koi WC; Chronic Program, Alexandra Hospital, National University Health System, Singapore, 159964.
Dong D; Vigilance & Compliance Branch, Health Sciences Authority, Singapore, 138667.
Sung C; Global Health Research Center, Duke Kunshan University, China, 215316.

Pharmacogenomics ; 21(4): 279-291, 2020 03.

Article in En | MEDLINE | ID: mdl-32180492

Subject(s)

Allopurinol/therapeutic use; Gout/drug therapy; Gout/genetics; HLA-B Antigens/genetics; Renal Insufficiency, Chronic/genetics; Aged; Aged, 80 and over; Cost-Benefit Analysis; Female; Genetic Testing; Genotype; Gout Suppressants/therapeutic use; Humans; Male; Middle Aged

Key words

HLA-B*5801 genotyping; StevensJohnson syndrome; chronic kidney disease; costeffectiveness; gout; toxic epidermal necrolysis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HLA-B Antigens / Allopurinol / Renal Insufficiency, Chronic / Gout Type of study: Health_economic_evaluation / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Pharmacogenomics Journal subject: FARMACOLOGIA / GENETICA MEDICA Year: 2020 Type: Article

Fulltext

XML

PubMed Links

Search on Google